A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer
NCT06840535
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
20
Enrollment
INDUSTRY
Sponsor class
Conditions
Prostate Cancer
Prostate Cancer Metastatic Disease
PSA Level Greater Than 0.2
Interventions
DRUG:
[68Ga]Ga-OncoACP3
Sponsor
Philogen S.p.A.